Press

Filament Health Announces New United States Patent Issuances

Nov 30 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament’s latest patents were issued by the United States Patent and Trademark Office (USPTO) and describe…

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America

Nov 30 • 7 min read

Braxia Scientific Corp., (CSE: BRAX | OTC: BRAXF | FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the second quarter ended September 30, 2022. Complete financial statements along with…

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

Nov 30 • 10 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and twelve months ended August 31, 2022 (“Q4 2022” and “Fiscal 2022”). “Fiscal 2022 was a pivotal year for Numinus, as we entered the US market with the transformational…

Psyrise Launches the First End-To-End Marketing Platform for Ketamine Clinics, Retreats, and Psychedelic-Assisted Therapists

Nov 30 • 4 min read

Psyrise, a mental health marketing company located in South Florida, has released a first-of-its-kind marketing platform for health practitioners. The platform was previously used internally by the company and piloted by a handful of select practitioner partners. This broader release will now allow 25 more groups to onboard as preferred partners. Psyrise launched in January as…

Wellbeing Subsidiary Mindscape Treats its 1,000th Patient

Nov 29 • 3 min read

Wellbeing Digital Sciences Inc. (NEO: MEDI) OTC: KONEF | FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its subsidiary Mindscape Ketamine & Infusion Therapy, PLLC, has treated its 1,000th patient with IV Ketamine Therapy for treatment-resistant mood…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441